WAVE Life Sciences Ltd (FRA:1U5)
€ 12.8 -0.1 (-0.78%) Market Cap: 1.89 Bil Enterprise Value: 1.62 Bil PE Ratio: 0 PB Ratio: 13.52 GF Score: 41/100

WAVE Life Sciences Ltd to Host Analyst and Investor Research Day Transcript

Oct 07, 2019 / 05:00PM GMT
Paul B. Bolno
Wave Life Sciences Ltd. - President, CEO & Director

(presentation)

And first and foremost, welcome. Thank you for taking the time out of all of your day. For everyone in this room, I'm grateful. We're grateful. I know you all have busy schedules, so we appreciate you spending some time with us to learn about what's happening at Wave. To those of you who are logged on to the webcast, we appreciate you taking the time out of your day as well and we hope to have it to be a productive one.

To make it productive, we'll quickly talk about some forward-looking statements. We will be making forward-looking statements during this presentation. So again, please refer to our SEC filings for current updates.

And with that said, I know many of you are here eagerly awaiting our clinical data for duchenne muscular dystrophy, our exon 51 suvodirsen program as well as our HD program. We are too. And it's important for you all to know that we remain on track for delivering that data this year. We anticipate delivering the suvodirsen biopsy data from our ongoing open-label

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot